Compare Novartis AG (NVS) vs Vanguard Intermediate Term Corporate Bond ETF (VCIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Vanguard Intermediate Term Corporate Bond ETF — how do they compare? Novartis AG trades at $153.88 (market cap $290.25B), while Vanguard Intermediate Term Corporate Bond ETF trades at $81.54. The key difference: Novartis AG pays a 3.17% dividend while Vanguard Intermediate Term Corporate Bond ETF pays none, and Novartis AG is trading nearer its 52-week high, Vanguard Intermediate Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| NVS | VCIT | |
|---|---|---|
Market Cap | $290.25B | — |
Sector | Health | Fixed Income |
52-Week High | $168.62 | $84.82 |
52-Week Low | $113.50 | $81.45 |
Enterprise Value | $330.27B | — |
Dividend Yield | 3.17% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Vanguard Intermediate Term Corporate Bond ETF
VCIT tracks the Bloomberg U.S. 5-10 Year Corporate Bond Index, providing exposure to investment-grade debt from industrial, utility, and financial companies. It acts as a middle-ground bond fund, offering higher yields than short-term bonds with less price volatility than long-term corporate debt.
Read more on VCIT →
